Clinuvel Pharmaceuticals Ltd.
CUVL - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$359.47M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $359.47 Million |
|---|---|
| Enterprise Value | $323.71 Million |
| Annual dividend | $0.03 |
| Dividend yield | 0.73% |
| Earnings per Share | $- |
| Beta | 0.57 |
| Outstanding Shares | - |
Return
| Return on Equity | 28.59% |
|---|---|
| Return on Assets | 26.40% |
| Return on Invested Capital | 36.30% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.73 |
| Enterprise Value to EBIT | 3.54 |
| Enterprise Value to Net Income | 4 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 26, 2026
EPS Estimate
$0.35
Consensus analyst estimateRevenue Estimate
$42.23 M
Consensus analyst estimateNext Earnings Call
Expected Date
February 23, 2027
EPS Estimate
$0.18
Consensus analyst estimateRevenue Estimate
$26.01 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Clinuvel Pharmaceuticals Limited
109 employees
CEO: Philippe Jacques Wolgen
Clinuvel Pharmaceuticals Limited (CLVLF), an Australian biopharmaceutical firm established in Melbourne in 1987, specializes in the creation and global marketing of therapeutic solutions. Its primary focus is on patients suffering from g...